Malay Gandhi

Malay Gandhi is the Strategist in Residence at Rock Health, where he works with Rock Health portfolio companies to develop sustainable business models. He is currently on sabbatical from Deloitte Consulting, where he advises leading healthcare companies on innovation and growth.

Recent posts

Your Car: The Future of Connected Health?
The car is entering an innovation renaissance. While Tesla Motors—the electric car company led by PayPal founder Elon Musk—has become the emblem of auto innovation, other manufacturers are following suit. For... Read more »

Page 1 of 1

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

Sponsored · Whitepaper
Potency Assay Development for Cell and Gene Therapy Products
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems

Sponsored · Whitepaper
What to Include in Your Life Sciences Company Fundraising Pitch Deck
What the most successful life sciences fundraising pitch decks all have in common
Brex

Xconomy on Demand

We offer a number of ways to subscribe for free!

Subscribe Now

Xconomy National

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period

BioNTech's mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data

CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy

Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better

MEI Pharma, Helsinn Scuttle Cancer Drug Trial After Miss on Efficacy

On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO

Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug

Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash

Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage

Akili Interactive’s Video Game for ADHD Gets the FDA All Clear

Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs

The 2020 National Xconomy Awards

Xcelerating Life Sciences Seattle

Xcelerating Life Sciences New York

Malay Gandhi

Recent posts

Your Car: The Future of Connected Health?

Underwriters and Partners

Decentralized Clinical Trials: The Call for a New Paradigm

Potency Assay Development for Cell and Gene Therapy Products

What to Include in Your Life Sciences Company Fundraising Pitch Deck

Xconomy on Demand

We offer a number of ways to subscribe for free!